Myriad Genetics vs Tempus (2026)
GeneSight, from Myriad Genetics, and Tempus nP are both pharmacogenomic tests a prescriber orders to guide psychiatric medication choices, and what decides between them is what comes back alongside the genetic result. GeneSight Psychotropic, sold through Myriad Neuroscience, uses combinatorial pharmacogenomics to report how a patient's genes may affect more than 60 medications approved for depression, anxiety, ADHD and other conditions. A registered prescribing clinician orders it, results usually reach the clinician about two days after the sample arrives, and 98 percent of patients pay $330 or less, with Myriad calling first if the cost would run higher. Its evidence was gathered in patients with major depressive disorder who had already failed at least one medication, and Myriad's tests order and result inside Epic, athenahealth and other record systems. Tempus nP reads 13 pharmacogenomic genes from a cheek swab or saliva sample in Tempus's own laboratory. Each report comes with Tempus PRO, which tracks how the patient responds to treatment afterward, and results sit in Tempus Hub beside those assessments, with a self pay price of $295. A practice that wants a report spanning more than 60 medications, a capped patient cost and ordering from its record system fits GeneSight. A practice that wants the genetic result joined to ongoing tracking of treatment response fits Tempus nP.
- The prescriber wants a report spanning more than 60 psychiatric medications.
- Patients need a cost cap, with a call before any bill above the usual amount.
- Orders should flow from Epic, athenahealth or another connected record system.
- The patient has major depressive disorder and has already failed at least one medication.
- The practice wants to track treatment response after the test.
- Uninsured patients need a set self pay price.
- Results should sit in one physician portal beside patient assessments.
- Clinicians also want a notetaker built for psychiatry visits.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Myriad Genetics and Tempus are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Myriad Genetics | Tempus |
|---|---|---|
| Primary category | Diagnostics & Genomics | Clinical Decision Support |
| Founded | 1991 | Not recorded |
| Headquarters | Salt Lake City, Utah, United States | Chicago, Illinois |
| Website | myriad.com | tempus.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Myriad Genetics is a genetic testing company in Salt Lake City, Utah, listed on NASDAQ as MYGN, that runs its tests in its own accredited laboratories. Most of what it sells is laboratory testing: the MyRisk hereditary cancer panel, GeneSight pharmacogenomic testing for mental health medications, Prequel prenatal screening, the Foresight carrier screen, Precise Tumor profiling, Precise MRD monitoring and the MyChoice CDx companion diagnostic.
Source: AI Health Index, October 2026
Tempus is a precision medicine company listed on NASDAQ as TEM and based in Chicago, whose core business is molecular laboratory testing. Next reads unstructured record data to find patients who have not received guideline directed care, starting with biomarker testing in oncology, and surfaces them to physicians and precision medicine teams; a prospective study of 662 lung cancer patients in six community health systems, presented at ASCO 2026, reported higher biomarker testing rates.
Source: AI Health Index, October 2026
Questions buyers ask
Is GeneSight or Tempus nP better for choosing psychiatric medications?
GeneSight suits a practice that wants a report spanning more than 60 medications for depression, anxiety, ADHD and other conditions, a capped patient cost and ordering from Epic or athenahealth. Tempus nP suits a practice that wants the genetic result joined to Tempus PRO, which tracks how the patient responds to treatment afterward. Both are laboratory developed tests that inform rather than replace the prescriber's judgment. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
How much do GeneSight and Tempus nP cost?
Myriad says 98 percent of GeneSight patients pay $330 or less, and it calls the patient first if the cost would run higher. Tempus offers nP at a self pay price of $295. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
What do GeneSight and Tempus nP test?
GeneSight Psychotropic uses combinatorial pharmacogenomics to report how a patient's genes may affect more than 60 medications approved for depression, anxiety, ADHD and other conditions. Tempus nP reads variants in 13 pharmacogenomic genes from a cheek swab or saliva sample in Tempus's own laboratory. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
Who can order GeneSight or Tempus nP, and how fast do results come back?
GeneSight must be ordered by a prescribing clinician who is registered to offer it, and results usually reach the clinician about two days after the sample arrives. Tempus nP must be ordered by a healthcare provider through Tempus, and the results return to Tempus Hub beside the patient's assessment results. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
Which patients does the GeneSight evidence cover?
GeneSight's evidence was gathered in patients with major depressive disorder who had already failed at least one medication. Myriad sells it through Myriad Neuroscience, the trade name of its Assurex Health subsidiary. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Myriad Genetics, listed on NASDAQ as MYGN and based in Salt Lake City, sells GeneSight through Myriad Neuroscience, the trade name of its Assurex Health subsidiary. Tempus, listed on NASDAQ as TEM, is based in Chicago. Both tests are laboratory developed tests rather than FDA cleared devices, and both reports inform rather than replace the prescriber's judgment.